Issue link: http://viewer.e-digitaledition.com/i/884976
CARDIAC PACEMAKERS HAVE LONG BEEN A STANDARD TRE ATMENT FOR CERTAIN HE ART RHY THM DISORDERS. UNTIL RECENTLY, CONVENTIONAL TR ANSVENOUS PACEMAKERS WERE THE ONLY OPTION. UNFORTUNATELY, THESE CAN BE ASSOCIATED WITH VARIOUS COMPLICATIONS, SUCH AS LE AD ISSUES AND DISLODGEMENT, AS WELL AS INFECTION. THE MICR A, A LE ADLESS PACEMAKER IMPL ANTED DIRECTLY INTO THE HE ART, CAN HELP ELIMINATE THESE RISKS AND PROVIDE A SAFE ALTERNATIVE FOR MANY PATIENTS. T H E F D A A P P R O V E D this innovative technolog y — which is 93 percent smaller than traditional devices, according to the device manufacturer, Medtronic — in April 2016 for treatment of certain heart rhythm disorders. Cardiac electrophysiologists at Penn State Heart and Vascular Institute, Penn State Health Milton S. Hershey Medical Center, began utilizing the device in February 2017. MINIMALLY INVASIVE PLACEMENT Rather than place a generator subcutaneously over the chest and thread leads through the veins of the upper body to the heart, physicians use a minimally invasive, catheter-based system to implant the Micra pacemaker via the femoral vein. "We advance the pacemaker, which is preloaded in a delivery system, via groin access through the femoral vein to the heart," says Sarah Hussain, MD, cardiac electrophysiologist at Penn State Heart and Vascular Institute. "Once we test the device, check placement of the device on X-ray and are satisfied with its location, we release the device." The Micra is appropriate for patients who require single-chamber ventricular pacing. Candidates for Micra placement include those for whom transvenous leads are less desirable or are not an option — for example, those who are at an increased risk of infection or those who need to preserve their veins for hemodialysis or other future procedures. It can also be implanted following transvenous system removal due to faulty leads or lead dislodgement. AN ADVANTAGEOUS OPTION A planned interim analysis of an ongoing study published in The New England Journal of Medicine found significant di‡erences in complication rates when the Micra was compared with conventional transvenous pacing systems. Patients who received the Micra experienced fewer major complications during the six-month period following implantation. In addition, rates of subsequent hospitalizations, pacemaker system revisions and procedure- related events, due to device or lead dislodgement, were lower among patients who received Micra. The Micra is also associated with fewer activity restrictions because there is no risk of lead dislodgement during strenuous shoulder movement, according to Soraya Samii, MD, PhD, cardiac electrophysiologist at Penn State Heart and Vascular Institute. "Micra is changing how we manage patients who require these devices. It marks a new era in pacing systems," Dr. Samii says. "I believe Micra is the first of many leadless pacing systems to come onto the market." Visit hmc.pennstatehealth.org/heartandvascular or call 877-467-7484 for information about technologies used at Penn State Heart and Vascular Institute. ■ A Dedication to Advancement PENN STATE HE A RT A ND VA SCUL A R INSTITUTE features the only heart transplant center in the region, up-to- date technology and procedures, and a robust array of clinical trials and research opportunities. The adoption of the Micra pacemaker is another example of Penn State Health's commitment to innovation. "With access to the latest technologies, such as Micra, we can tailor treatments for each patient's specific needs and concerns," Dr. Hussain says. "We can pick and choose the right options for the right patients." NEW LEADLESS PACEMAKER Increases Options for Patients with Heart Rhythm Disorders BY TIFFANY PARNELL 1 2C A R D I A C C A R E

